CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
A=Placebo +4 moredrug
Likely dose
B=Inhaled Alprazolam 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02351115
NCT02351115Phase 2Completed
CompareCT.gov

Assessment of Staccato® Alprazolam on the EEG Photoparoxysmal Response in Patients With Epilepsy

Nova Pneuma Inc.·interventional·Posted Jan 30, 2015·Updated Apr 20, 2026

In Brief

A Phase 2 clinical trial evaluating A=Placebo, B=Inhaled Alprazolam 0.5 mg, and 3 other interventions for Epilepsy. Completed, enrolled 5 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
CollaboratorsThe Epilepsy Study Consortium

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 30, 2015
Enrollment StartJan 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.4 years ago

Interventions

A=Placebodrug

B=Inhaled Alprazolam 0.5 mgdrug

C=Inhaled Alprazolam 1 mdrug

D= Inhaled Alprazolam 2 mgdrug

E=Placebodrug